Relationship Between Botulinum Toxin, Spasticity, and Pain: a Survey of Patient Perception.

[OBJECTIVE] To assess the prevalence of pain in adults with spasticity and to assess the association between the subjective experience of pain and spasticity.

[DESIGN] Cross-sectional study.

[SETTING] outpatient spasticity management clinic of a rehabilitation centre.

[PATIENTS] Patients with upper motor neuron lesions and spasticity (n=131) were recruited.

[METHODS] We assessed pain intensity and location, relationship between spasticity and pain perception, and perception of pain relief from botulinum toxin type-A (BoNTA) injections.

[MAIN OUTCOME MEASURES] Pain perception rated on a 10-point numerical rating scale and pain quality.

[RESULTS] 65% of the patients with spasticity reported presence of pain and 60% described it as an aching pain. More patients reported pain with movement (34%) compared to rest (21%). There was a statistically poor correlation between the severity of pain and spasticity (r=0.16; p>0.05). Most patients (80%) believed that their pain was related to spasticity and 62% reported that BoNTA injections decreased their pain.

[CONCLUSIONS] The high incidence of pain noted within our sample suggests that physicians may have to consider pain management as part of spasticity treatment. Participants reported that their pain was related to their spasticity, and that it decreased after BoNTA treatment. Further study is needed to explore the relationships between objective measures of spasticity and pain.